Ventria Bioscience

Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The company was established in 1993 in Colorado. The company's core technology is a genetically modified crop-based protein production system (also called a "pharming" system or 'biopharming' ) called ExpressTec. They have also made applications to grow rice with human genes.

ExpressTec uses self-pollinating crops such as rice and barley to minimize the risk of gene flow normally associated with transgenic plants. Plant-produced proteins also offer advantages for cell culture and bioprocessing use because they replace animal derived components, which have become unpopular due to concerns about prion contamination.

Facilities
Ventria's corporate headquarters is in Denver, Colorado, with additional facilities in Kansas. On September 29, 2006, Kansas officials announced an agreement to bring Ventria’s new bioprocessing facility to Junction City, Kansas. Kansas Governor Kathleen Sebelius was supportive of the agreement and was quoted as stating "I welcome Ventria Bioscience to Kansas and look forward to their contributions to the health of children worldwide." The effort to attract Ventria to Kansas involved a number of players, including Governor Kathleen Sebelius, Secretary of Agriculture Adrian Polansky, The Kansas Department of Commerce, Junction City and Geary County, Kansas Technology Enterprise Corporation (KTEC), KansasBIO, Kansas State University, and Kansas Farm Bureau.

Divisions and Subsidiaries
Ventria created a new division of its company, called InVitria, in 2009. The division specialised in developing and commercialising animal-free cell culture supplements and reagents for use in the bio and life sciences industries. Applications for the products include cellular therapy, vaccines, medical devices, and regenerative medicine among others.

Markets and products
Human health, cell culture and biomanufacturing, and zoonotic disease are the three targeted markets for Ventria's products.

As of 2012 Ventria is developing six therapeutic products:
 * Human Health
 * VEN100 Recombinant human lactoferrin for antibiotic-associated diarrhea
 * VEN101 for Chemotherapy-Induced Diarrhea
 * VEN120 for Inflammatory Bowel Disease
 * VEN130 for Osteoporosis
 * VEN140 for Hepatic disease
 * VEN200 Optibumin Recombinant human albumin as a replacement for therapeutic human serum albumin

The company offers contract biomanufacturing services using its ExpressTec platform, and, through its subsidiary InVitria, sells a line of its proteins that it manufactures for the life sciences research market.

The company has conducted research in the field of zoonotic disease, specifically in lyme disease and rabies, with a goal of developing vaccines and offers some its recombinant proteins to life sciences researchers under a program called BioShare.

Funding
The company has been the recipient of grants and funding from organisations including the Bill & Melinda Gates Foundation, to develop their ExpressTec system.